Brain Advance Access published online on September 29, 2006
Brain, doi:10.1093/brain/awl251
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Pathology, The University of Melbourne and the Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
* To whom correspondence should be addressed. It is now 100 years since the nosological definition of Alzheimer's disease emerged. In the first 80 years, very little progress was made in understanding the mechanisms that caused the brain to degenerate in a remarkably specific fashion (amyloid accumulation with neurofibrillary changes). Over the past 20 years, there has been an explosion of knowledge which continues today at an exponential rate. The molecular pathways underlying the synaptic dysfunction in Alzheimer's disease have delivered many validated therapeutic and diagnostic targets. A variety of therapeutic strategies aimed at disease modification are now in clinical development.
Received July 3, 2006
Revised August 15, 2006
Accepted August 16, 2006
Review Article
Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A
Colin L. Masters 1 * and Konrad Beyreuther 2
amyloid pathway
2 Centre for Molecular Biology, The University of Heidelberg, Heidelberg, Germany
Colin L. Masters, E-mail: c.masters{at}unimelb.edu.au
![]()
Abstract
amyloid pathway; Alzheimer's disease; amyloid beta precursor protein.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
F. X. Guix, G. Ill-Raga, R. Bravo, T. Nakaya, G. de Fabritiis, M. Coma, G. P. Miscione, J. Villa-Freixa, T. Suzuki, X. Fernandez-Busquets, et al. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation Brain, May 1, 2009; 132(5): 1335 - 1345. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Robert, O. Dolezal, L. Waddington, M. K. Hattarki, R. Cappai, C. L. Masters, P. J. Hudson, and K. L. Wark Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers Protein Eng. Des. Sel., March 1, 2009; 22(3): 199 - 208. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Belinson, D. Lev, E. Masliah, and D. M. Michaelson Activation of the Amyloid Cascade in Apolipoprotein E4 Transgenic Mice Induces Lysosomal Activation and Neurodegeneration Resulting in Marked Cognitive Deficits J. Neurosci., April 30, 2008; 28(18): 4690 - 4701. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Pike, G. Savage, V. L. Villemagne, S. Ng, S. A. Moss, P. Maruff, C. A. Mathis, W. E. Klunk, C. L. Masters, and C. C. Rowe {beta}-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease Brain, November 1, 2007; 130(11): 2837 - 2844. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Hodges Alzheimer's centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspects. Brain, November 1, 2006; 129(Pt 11): 2811 - 2822. [Abstract] [Full Text] [PDF] |
||||


